Dear Ms. Wible:

Please refer to your New Drug Application (NDA) dated September 17, 2014, received September 17, 2015, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for IRESSA (gefitinib) 250 mg tablets.

We acknowledge receipt of your amendments dated September 25, October 3, November 3 and 12, December 9, 19, 23 and 24, 2014, and January 15 and 26, February 9 and 27, March 11, April 17, May 14, 19, 27 and 28, June 22 and 30, and July 9 and 10, 2015.

This new drug application provides for the use of IRESSA (gefitinib) 250 mg tablets for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. This approval includes the following limitation of use: Safety and efficacy of IRESSA have not been established in patients with metastatic NSCLC whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm). Content of labeling must be identical to the enclosed labeling text for the package insert and Medication Guide. Information on submitting SPL files using eLIST may be found in the guidance for industry [SPL Standard for Content of Labeling Technical Qs and As](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf).
The SPL will be accessible via publicly available labeling repositories.

**IMMEDIATE CONTAINER LABELS**

Submit final printed immediate container labels that are identical to the enclosed immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission **“Final Printed Container Labels for approved NDA 206995.”** Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit one market package of the drug product when it is available to the following address:

Sharon Sickafuse  
Food and Drug Administration  
Center for Drug Evaluation and Research  
White Oak Building 22, Room: 230810903 New Hampshire Avenue  
Silver Spring, Maryland  
*Use zip code 20903 if shipping via United States Postal Service (USPS).*  
*Use zip code 20993 if sending via any carrier other than USPS (e.g., UPS, DHL, FedEx).*

**DATING PERIOD**
The dating period for Iressa shall be 48 months from the date of manufacture for the 250 mg bottle containing 30 tablets when stored at controlled room temperature 20-25°C (68-77°F) [see USP].

**ADVISORY COMMITTEE**

Your application for IRESSA was not referred to an FDA advisory committee for the following reasons:

- IRESSA is not the first in its class;
- the evaluation of the safety data did not raise significant safety or efficacy issues in the intended population; and
- the application did not raise significant public health questions on the role of IRESSA in the treatment of a disease.
REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).
If you have any questions, please call Ms. Sharon Sickafuse, Senior Regulatory Health Project Manager, at (301) 796-2320.

Sincerely,

(See appended electronic signature page)

Patricia Keegan, M.D.
Director
Division of Oncology Products 2
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

Enclosures:
   Content of Labeling
   Container Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

PATRICIA KEEGAN
07/13/2015